TGFB1 and breast carcinoma: Therefore, an antibody domain that can recognize the three TGF-β isoforms can be advantageous and relevant from a therapeutic perspective1, Yang et al. reported a 75% metastasis suppression in 12 breast cancer models when Fresolimumab, a pan-specific TGF-β, was administrated18.